Michal Lotem

18.5k total citations · 2 hit papers
106 papers, 4.9k citations indexed

About

Michal Lotem is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Michal Lotem has authored 106 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 51 papers in Immunology and 43 papers in Molecular Biology. Recurrent topics in Michal Lotem's work include Immunotherapy and Immune Responses (39 papers), Cancer Immunotherapy and Biomarkers (39 papers) and CAR-T cell therapy research (37 papers). Michal Lotem is often cited by papers focused on Immunotherapy and Immune Responses (39 papers), Cancer Immunotherapy and Biomarkers (39 papers) and CAR-T cell therapy research (37 papers). Michal Lotem collaborates with scholars based in Israel, United States and Australia. Michal Lotem's co-authors include Jacob Schachter, Antoni Ribas, Georgina V. Long, Nageatte Ibrahim, Catriona M. McNeil, Adil Daud, Omid Hamid, Ana Arance, Matteo S. Carlino and Caroline Robert and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Nature Medicine.

In The Last Decade

Michal Lotem

102 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)

2017 898 citations Jacob Schachter, Antoni Ribas et al. profile →
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study

2019 768 citations Caroline Robert, Antoni Ribas et al. profile →

Peers

Countries citing papers authored by Michal Lotem

Since Specialization

Citations

This map shows the geographic impact of Michal Lotem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michal Lotem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michal Lotem more than expected).

Fields of papers citing papers by Michal Lotem

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michal Lotem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michal Lotem. The network helps show where Michal Lotem may publish in the future.

Co-authorship network of co-authors of Michal Lotem

This figure shows the co-authorship network connecting the top 25 collaborators of Michal Lotem. A scholar is included among the top collaborators of Michal Lotem based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michal Lotem. Michal Lotem is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Unveiling alternative splicing dynamics in activated T lymphocytes and their implications for immune checkpoint blockade efficacy 2025 ·iScience ·(unknown), Otto Stern, (unknown), (unknown), Thomas Eisenhaure, Sarah E. Henrickson, Moshe Sade-Feldman, (unknown), Galit Eisenberg, Nir Hacohen, Keren Yizhak, Michal Lotem	0
2	Alternative splicing of modulatory immune receptors in T lymphocytes: a newly identified and targetable mechanism for anticancer immunotherapy 2025 ·Frontiers in Immunology ·(unknown), Otto Stern, (unknown), Galit Eisenberg, Shiri Klein, Shoshana Frankenburg, Michal Lotem	2
3	Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events 2024 ·Journal for ImmunoTherapy of Cancer ·Limor Rubin, (unknown), (unknown), David Lavie, Hovav Nechushtan, Nadia Caplan, Michal Lotem, Oded Shamriz, Irit Adini, Yuval Tal	2
4	The future of affordable cancer immunotherapy 2023 ·Frontiers in Immunology ·Niels Schaft, Jan Dörrie, Gerold Schuler, Beatrice Schuler‐Thurner, (unknown), Shiri Klein, Galit Eisenberg, Shoshana Frankenburg, Michal Lotem, (unknown)	38
5	Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions 2023 ·Science Translational Medicine ·(unknown), Liza Weinstein‐Fudim, (unknown), (unknown), (unknown), (unknown), Shoshana Frankenburg, Tamar Peretz, Galit Eisenberg, Michal Lotem, Ofra Benny, Sharon Merims	0
6	Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma 2023 ·Journal of Clinical Oncology ·Caroline Robert, Matteo S. Carlino, Catriona M. McNeil, Antoni Ribas, Jean‐Jacques Grob, Jacob Schachter, Marta Nyakas, Damien Kee, Teresa M. Petrella, (unknown), Michal Lotem, Ana Arance, Adil Daud, Omid Hamid, James Larkin, James R. Anderson, Clemens Krepler, Dmitri Grebennik, Georgina V. Long	63
7	A subset of neutrophils as a predictive biomarker for immunotherapy response in patients with non–small-cell lung cancer and melanoma. 2023 ·Journal of Clinical Oncology ·Yuval Shaked, Madeleine Benguigui, Ruth Halaban, Antonella Bacchiocchi, Iris Kamer, Jair Bar, Michal Lotem, Shai S. Shen-Orr, Mario Sznol, Tim J. Cooper	1
8	Alternative Splicing of the Inhibitory Immune Checkpoint Receptor SLAMF6 Generates a Dominant Positive Form, Boosting T-cell Effector Functions 2021 ·Cancer Immunology Research ·Emma Hajaj, (unknown), (unknown), Sharon Merims, Jonathan Cohen, Shiri Klein, Shoshana Frankenburg, Moshe Sade-Feldman, Yuval Tabach, Keren Yizhak, Ami Navon, Polina Stepensky, Nir Hacohen, Tamar Peretz, André Veillette, Rotem Karni, Galit Eisenberg, Michal Lotem	14
9	TP53 missense mutations in PDAC are associated with enhanced fibrosis and an immunosuppressive microenvironment 2021 ·Proceedings of the National Academy of Sciences ·(unknown), Giuseppe Mallel, Nishanth Belugali Nataraj, Michal Shreberk‐Shaked, Ori Hassin, Saptaparna Mukherjee, Sharathchandra Arandkar, Ron Rotkopf, (unknown), (unknown), (unknown), (unknown), Ofra Golani, Yoseph Addadi, Emma Hajaj, Raya Eilam, Ravid Straussman, Yosef Yarden, Michal Lotem, Moshe Oren	72
10	KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma 2020 ·Journal for ImmunoTherapy of Cancer ·Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, (unknown), Inge Marie Svane, Michal Lotem, (unknown), Eduard Gasal, Razi Ghori, Scott J. Diede, (unknown), Antoni Ribas, Paolo A. Ascierto	111
11	1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours 2020 ·Annals of Oncology ·Hani M. Babiker, Erkut Borazanci, Vivek Subbiah, Alain P. Algazi, Jacob Schachter, Michal Lotem, Daniel Hendler, (unknown), Hans Minderman, Cara Haymaker, Chantale Bernatchez, Ravi Murthy, (unknown), Nadia Caplan, Gregory Woodhead, (unknown), Srinivas K. Chunduru, Peter M. Anderson, Adi Diab, Igor Puzanov	2
12	Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma 2019 ·Nature Medicine ·Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V. Long, Anna Maria Di Giacomo, Inge Marie Svane, Michal Lotem, Gil Bar‐Sela, Félix Couture, Bijoyesh Mookerjee, Razi Ghori, Nageatte Ibrahim, Blanca Homet Moreno, Antoni Ribas	219
13	Soluble SLAMF6 Receptor Induces Strong CD8+ T-cell Effector Function and Improves Anti-Melanoma Activity In Vivo 2018 ·Cancer Immunology Research ·Galit Eisenberg, (unknown), (unknown), Emma Hajaj, Sharon Merims, Shoshana Frankenburg, (unknown), (unknown), Arthur Machlenkin, (unknown), Tamar Peretz, Michal Lotem	19
14	Potent Activation of Human T Cells by mRNA Encoding Constitutively Active CD40 2018 ·The Journal of Immunology ·Noam Levin, (unknown), (unknown), Orit Itzhaki, Michal J. Besser, Galit Eisenberg, Tamar Peretz, Michal Lotem, Gideon Gross	12
15	Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients 2016 ·Annals of Oncology ·Aviad Zick, Tamar Peretz, Michal Lotem, (unknown), (unknown), Mark Temper, Yakir Rottenberg, Beatrice Uziely, Hovav Nechushtan, Amichay Meirovitz, Amir Sonnenblick, Eli Sapir, Daniel C. Edelman, Yael Goldberg, Alexander Lossos, S. Rosenberg, Iris Fried, (unknown), Eli Pikarsky, Hanoch Goldshmidt	1
16	The Clinical Effect of the Inhibitor of Apopotosis Protein Livin in Melanoma 2012 ·Oncology ·(unknown), Riki Perlman, Michal Lotem, Tamar Peretz, Dina Ben‐Yehuda, Luna Kadouri	27
17	Long-term survival of uveal melanoma patients after surgery for liver metastases 2009 ·British Journal of Ophthalmology ·Shahar Frenkel, I. Nir, Karen Hendler, Michal Lotem, Ali H. Eid, (unknown), J. Pe’er	80
18	Viral Carcinogenesis in Skin Cancer 2007 ·Current Problems in Dermatology ·Vered Molho‐Pessach, Michal Lotem	16
19	Post Hepatectomy Survival of Metastatic Uveal Melanoma Patients 2006 ·Investigative Ophthalmology & Visual Science ·J. Pe’er, (unknown), Michal Lotem, Robert Folberg, Shahar Frenkel	1
20	Cytogenetic analysis of melanoma cell lines 2003 ·Cancer Genetics and Cytogenetics ·Michal Lotem, (unknown), (unknown), Olga Drize, Tamar Peretz, Dvorah Abeliovich	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact